Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2025)

Avalo Therapeutics (AVTX) has disclosed Deferred Taxes for 9 consecutive years, with $10000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Deferred Taxes rose 171.43% year-over-year to $10000.0, compared with a TTM value of $148000.0 through Sep 2025, up 1744.44%, and an annual FY2024 reading of $114000.0, up 714.29% over the prior year.
  • Deferred Taxes was $10000.0 for Q3 2025 at Avalo Therapeutics, down from $16000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $114000.0 in Q4 2024 and bottomed at -$62000.0 in Q4 2021.
  • Average Deferred Taxes over 5 years is $8842.1, with a median of $8000.0 recorded in 2022.
  • Peak annual rise in Deferred Taxes hit 1366.67% in 2024, while the deepest fall reached 275.0% in 2024.
  • Year by year, Deferred Taxes stood at -$62000.0 in 2021, then skyrocketed by 112.9% to $8000.0 in 2022, then plummeted by 212.5% to -$9000.0 in 2023, then surged by 1366.67% to $114000.0 in 2024, then plummeted by 91.23% to $10000.0 in 2025.
  • Business Quant data shows Deferred Taxes for AVTX at $10000.0 in Q3 2025, $16000.0 in Q2 2025, and $8000.0 in Q1 2025.